Nanoform Finland Plc and Celanese Corporation provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery. Together, the API nanoparticles produced through Nanoform's CESS® technology and the Celanese VitalDose® EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nano formed particles also allows smaller implants with sustained release properties to be developed.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.948 EUR | +0.31% | -5.89% | +22.90% |
Apr. 11 | Nanoform Finland to Deliver Nanomedicine Technology to Japan | MT |
Apr. 11 | Nanoform Enters Exclusive Partnership with CBC to Bring Best-In-Class Nanomedicine Technology to Japan | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
156.7 USD | -2.93% | -0.31% | 17.11B | ||
1.948 EUR | +0.31% | -5.89% | 179M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.90% | 179M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+46.28% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- NANOFH Stock
- News Nanoform Finland Oyj
- Nanoform and Celanese Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants